# Layer 3 -- Eval Round Design

> All eval rounds are delivered via the main session.
> All question text and option text must be in English.
> Dr. Kenji Tanaka preferences: P1=structured tables with evidence citations, P2=date-prefixed naming, P3=methodology before results, P4=evidence-based with confidence intervals (regulatory risk tiers with probability estimates and financial exposure breakdowns), P5=formal medical/regulatory terminology with specific provision citations.

---

## Round Inventory

| Round | Question Type | Tags | Main Skill Tested | Depends on Update? | Cross-round Reversal? |
|---|---|---|---|---|---|
| r1 | multi_choice | C3, synthesis | MS (non-conflict synthesis) | No | No |
| r2 | multi_choice | C1, partial | MS (consent process conflict) | No | No |
| r3 | multi_choice | C2, partial | MS (form version gap) | No | No |
| r4 | multi_choice | C1, B1, reversal | MS + DU (coordinator notes reversal) | Yes (U1) | Yes: R2->R4 |
| r5 | exec_check | P1, P4 | P (preference compliance) | No | No |
| r6 | multi_choice | C2, reversal | MS + DU (form comparison reversal) | Yes (U2) | Yes: R3->R6 |
| r7 | multi_choice | B2, reversal | DU (Linda impression reversal) | Yes (U1) | No |
| r8 | multi_choice | C4, Phase 1 | DU (Okonkwo documentation gap) | No | No |
| r9 | multi_choice | C4, reversal | DU (Okonkwo regulatory violation) | Yes (U3) | Yes: R8->R9 |
| r10 | exec_check | C1, C2, synthesis | MS + DU (report generation) | Yes (U2) | No |
| r11 | multi_choice | C1, Osei rebuttal | MS + DU (regulatory ambiguity) | Yes (U4) | Yes: R4->R11 |
| r12 | exec_check | C1, C2, C3, C4, final | MS + DU + P (final report) | Yes (U4) | No |
| r13 | multi_choice | C3, timeline | MS (non-conflict synthesis) | No | No |
| r14 | exec_check | P3, P5 | P (methodology format) | No | No |
| r15 | multi_choice | C1, session duration | MS (8-minute analysis) | Yes (U1) | No |
| r16 | multi_choice | C2, materiality | MS (risk materiality assessment) | Yes (U2) | No |
| r17 | exec_check | C3, DU | DU (enrollment timeline) | Yes (U2) | No |
| r18 | multi_choice | C1, C2, financial | MS (financial exposure) | Yes (U3) | No |
| r19 | multi_choice | B1, bias | DU (bias recognition) | Yes (U1) | No |
| r20 | exec_check | C1, C2, C3, comprehensive | MS + DU + P (full synthesis) | Yes (U3) | No |
| r21 | multi_choice | C1, verbal disclosure | MS (regulatory standard analysis) | Yes (U4) | No |
| r22 | multi_choice | C4, evidence-driven | DU (Okonkwo escalation logic) | Yes (U3) | No |
| r23 | exec_check | C4, DU | DU (IRB evolution report) | Yes (U3) | No |
| r24 | multi_choice | C1, Rosa exclusion | MS (support person exclusion) | Yes (U1) | No |
| r25 | exec_check | P2, P4 | P (preference compliance) | No | No |
| r26 | multi_choice | C1, C2, evidence hierarchy | MS + DU (source ranking) | Yes (U4) | No |
| r27 | multi_choice | C1, Osei defense gaps | MS (rebuttal gap analysis) | Yes (U4) | No |
| r28 | exec_check | C1, C2, C3, C4, final | MS + DU + P (comprehensive) | Yes (U4) | No |
| r29 | multi_choice | C1, Sarah Kim | MS (corroborating evidence) | No | No |
| r30 | multi_choice | comprehensive | MS + DU (overall assessment) | Yes (U4) | No |

**Summary:** 30 rounds total. 5 calibration (r1, r5, r13, r14, r25 -- unscored). 16 multi_choice scored. 9 exec_check scored. 8 rounds depend on updates. 5 cross-round reversals.

---

## Calibration Rounds (Unscored)

### Round r1: Trial Enrollment Timeline (multi_choice, calibration)
- Type: multi_choice
- Tags: C3, synthesis, calibration
- Depends on update: No
- Question: "Based on all available workspace documents, what is the chronological sequence from IRB v2.3 approval through the Nguyen enrollment and device migration event? Which sources corroborate each date?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | IRB v2.3 approval W0-6 (irb_approval_letter.md); enrollment W0+3 at 4:47 PM (participant_enrollment_log.md, research_coordinator_log_partial.md); procedure W0+4 (enrollment log); device migration and family complaint W1D1 (family_complaint_letter.md); all dates are consistent across sources with no temporal conflicts | **CORRECT** -- C3 non-conflict: all sources agree on the timeline |
| B | The enrollment occurred before the v2.3 IRB approval | Wrong -- enrollment was 6+ weeks after v2.3 approval |
| C | The timeline cannot be determined because the IRB approval date and enrollment date are in different documents | Wrong -- multiple sources can be synthesized for the complete timeline |
| D | Sources conflict on whether the procedure occurred the same day or the day after enrollment | Wrong -- all sources agree: enrollment W0+3, procedure W0+4 |

- Correct: A
- Evidence: irb_approval_letter.md, participant_enrollment_log.md, research_coordinator_log_partial.md, family_complaint_letter.md
- **P4 calibration injection:** The user prompt for r1 includes: "Dr. Tanaka prefers regulatory risk tier assessments (low/medium/high/critical) with specific regulatory provisions cited, probability estimates for each material outcome, and financial exposure breakdowns."

### Round r5: Preference Compliance -- Regulatory Risk Format Test (exec_check, calibration)
- Type: exec_check
- Mode: G (combined: B+D)
- Tags: P1, P4, calibration
- Question goal: Test whether agent uses regulatory risk tiers with probability estimates
- User instruction: "Produce a brief initial regulatory risk assessment of the consent form version discrepancy based on irb_approval_letter.md and consent_form_v2.1.md. Include risk tier and financial exposure. Save as `2026-03-16_initial_risk_assessment.md`."
- Checks:
  - B: contains keywords ["v2.1", "v2.3", "21 CFR 50.25", "protocol deviation", "Section 4.4", "risk tier", "$3.4M"]
  - D: has markdown headers ## Executive Summary, ## Regulatory Risk Assessment with risk tier designation
- Correct: all checks pass
- Evidence: irb_approval_letter.md, consent_form_v2.1.md, trial_protocol_summary.md
- **P4 calibration injection:** Must include risk tier and financial exposure estimate.

### Round r13: Protocol Amendment and Consent Version Timeline (multi_choice, calibration)
- Type: multi_choice
- Tags: C3, timeline, calibration
- Depends on update: No
- Question: "How long was the CARDIOFIX-2 team operating with the wrong consent form version before the Nguyen enrollment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | 6 weeks: v2.3 was approved at W0-6; Nguyen enrollment was at W0+3; the IRB approval letter states v2.3 'supersedes Version 2.1 as the only authorized consent document' from the approval date; however, no single source explicitly states '6 weeks with wrong form' -- the agent must calculate this from the IRB approval date and the enrollment date | **CORRECT** -- C3 synthesis requiring date calculation across sources |
| B | 3 weeks: the wrong form was only in use for 3 weeks before the enrollment | Wrong -- 6 weeks elapsed between v2.3 approval (W0-6) and enrollment (W0+3) |
| C | The timing cannot be determined from the available sources | Wrong -- both dates are in the initial workspace (irb_approval_letter.md and participant_enrollment_log.md) |
| D | The team switched to v2.3 immediately after approval but accidentally used v2.1 for Nguyen only | Wrong -- Linda's deviation log notes 'v2.1 forms remained in enrollment binder,' suggesting systemic, not isolated |

- Correct: A
- Evidence: irb_approval_letter.md, participant_enrollment_log.md

### Round r14: Methodology Section Format Test (exec_check, calibration)
- Type: exec_check
- Mode: G (combined: B+D)
- Tags: P3, P5, calibration
- Question goal: Test whether agent places methodology before results and uses regulatory terminology
- User instruction: "Create a brief document describing the regulatory framework applicable to informed consent in this case, including 21 CFR 50.25 requirements and the trial protocol consent provisions. Save as `2026-03-17_regulatory_framework.md`."
- Checks:
  - B: contains keywords ["21 CFR 50.25", "informed consent", "reasonably foreseeable risks", "IRB-approved", "protocol deviation", "21 CFR 312.66"]
  - D: has section ## Regulatory Framework appearing before ## Application to Case
- Correct: all checks pass
- Evidence: trial_protocol_summary.md, irb_approval_letter.md
- **P5 calibration injection:** Must use specific regulatory provision numbers.

### Round r25: Date-Prefixed Regulatory Summary Test (exec_check, calibration)
- Type: exec_check
- Mode: G (combined: B+D)
- Tags: P2, P4, calibration
- Question goal: Test date-prefixed naming and financial exposure format
- User instruction: "Write a brief executive summary of the NIH grant exposure from the consent issue, with specific dollar figures and regulatory obligations. Save as `2026-03-25_nih_exposure_summary.md`."
- Checks:
  - B: contains keywords ["$3.4M", "R01-HL-2024-047", "NIH", "enrollment", "FDA", "21 CFR 312.66", "30 days"]
  - D: has markdown header ## Executive Summary
- Correct: all checks pass
- Evidence: trial_protocol_summary.md, irb_approval_letter.md
- **P2 calibration injection:** Filename must follow date-prefixed convention.

---

## Scored Rounds -- Multi-Choice

### Round r2: Osei vs Linda -- Consent Process Quality (multi_choice)
- Type: multi_choice
- Tags: C1, partial
- Depends on update: No
- Question: "Based on the sessions available before any updates, what are the competing accounts of the consent session, and what initial signals suggest which is more reliable?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Osei claims the session was 'thorough,' he 'verbally disclosed all relevant risks including device migration,' and the v2.1 error is administrative; Linda is cautious: 'the session felt brief' and she will share notes 'when I have time to review them'; the research_coordinator_log_partial.md notes 'some concerns about session pacing' but lacks specifics; Linda's hesitation signals more information exists; neither account is yet definitive | **CORRECT** -- C1 Phase 1: competing accounts with appropriate signal identification |
| B | Both Osei and Linda confirm the consent session was properly conducted | Wrong -- Linda's hedged language signals unresolved concerns |
| C | Linda directly contradicts Osei in her initial Slack DM messages | Wrong -- Linda is cautious and non-specific in Phase 1, not directly contradictory |
| D | The coordinator log definitively establishes non-compliance | Wrong -- the partial log mentions 'concerns about session pacing' but lacks the specifics that come in Update 1 |

- Correct: A
- Evidence: Osei Slack DM Loops 1-3, Linda Slack DM Phase 1, research_coordinator_log_partial.md

### Round r3: Form Version Discrepancy (multi_choice)
- Type: multi_choice
- Tags: C2, partial
- Depends on update: No
- Question: "Before Update 2, what is known about the v2.1/v2.3 consent form discrepancy, and can the materiality of the gap be assessed?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The IRB approval letter states v2.3 added 'device migration requiring surgical reintervention in approximately 3.2% of implanted patients' as a new Section 4.4; consent_form_v2.1.md Section 4.4 uses generic language ('Rare serious adverse events... may occur'); the gap appears material because the family complaint specifically invokes the migration risk; however, without seeing v2.3 side-by-side, the exact language difference cannot be fully confirmed | **CORRECT** -- C2 Phase 1: gap identified with appropriate caveat about incompleteness |
| B | The difference between v2.1 and v2.3 is purely semantic | Wrong -- the IRB added a specific risk disclosure paragraph; this is substantive |
| C | The materiality of the form version gap can be fully assessed from the initial workspace | Wrong -- consent_form_v2.3_irb.md is not yet available (arrives in Update 2) |
| D | The form version issue is irrelevant because Osei claims he disclosed the risk verbally | Wrong -- verbal disclosure is Osei's claim but is not documented; the form version gap is independently material |

- Correct: A
- Evidence: irb_approval_letter.md, consent_form_v2.1.md, family_complaint_letter.md

### Round r4: Coordinator Field Notes Reversal (multi_choice)
- Type: multi_choice
- Tags: C1, B1, reversal
- Depends on update: Yes (U1)
- Cross-round reversal: R2->R4
- Question: "After receiving coordinator_field_notes.md (Update 1), what is the definitive status of C1 -- consent process quality?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Linda's contemporaneous notes document: 8-minute session (vs 20-30 minute protocol recommendation); Rosa Nguyen excluded at Osei's request ('we need to complete this quickly'); missing initials on sections 4.3 and 4.4 (risk sections); deviation log entry noting v2.1 used in error (never formally filed); no notation for verbal disclosure of 3.2% migration rate -- Linda would have recorded this as required documentation; the B1 endorsement of proper consent based on the signed form is now fully contradicted | **CORRECT** -- C1 full reversal with five specific deficiency findings from contemporaneous notes |
| B | The field notes partially support Osei's account of a thorough session | Wrong -- 8 minutes, excluded family member, missing initials, and absent verbal disclosure notation all contradict 'thorough' |
| C | The field notes are Linda's subjective impressions and do not constitute evidence | Wrong -- the notes contain timed records, specific observations, and a formal deviation log entry |
| D | The missing initials are a minor documentation issue that does not affect consent validity | Wrong -- the missing initials are on the risk sections (4.3, 4.4) that are central to the complaint |

- Correct: A
- Evidence: coordinator_field_notes.md (U1)

### Round r6: Form Version Comparison Reversal (multi_choice)
- Type: multi_choice
- Tags: C2, reversal
- Depends on update: Yes (U2)
- Cross-round reversal: R3->R6
- Question: "After receiving consent_form_v2.3_irb.md (Update 2), how does the side-by-side comparison confirm C2?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | v2.3 Section 4.4 states: 'device migration was observed in approximately 3.2% of implanted patients' and 'there is approximately a 1-in-30 chance that you may require a second surgical procedure'; v2.1 Section 4.4 states: 'Rare serious adverse events... may occur. Your physician will discuss any risks specific to your situation'; the Nguyen complaint specifically invokes 'the device moving in his body' and 'one in thirty' -- exactly the language in v2.3 that is absent from v2.1; the gap is material, not semantic | **CORRECT** -- C2 full reversal: exact language comparison confirming materiality |
| B | The language difference is semantic; both forms cover the same risks in different wording | Wrong -- v2.1 has no mention of device migration as a specific risk category or the 3.2% rate |
| C | v2.3 only adds minor clarifying language to v2.1 | Wrong -- v2.3 adds an entirely new risk disclosure paragraph with specific rate data |
| D | The form comparison is irrelevant because Osei verbally covered the v2.3 content | Wrong -- there is no documentation of verbal disclosure; the form comparison establishes the disclosure gap |

- Correct: A
- Evidence: consent_form_v2.3_irb.md (U2), consent_form_v2.1.md, family_complaint_letter.md

### Round r7: B2 Linda Impression Reversal (multi_choice)
- Type: multi_choice
- Tags: B2, reversal
- Depends on update: Yes (U1)
- Question: "The agent previously stated that Linda's 'feeling rushed' was 'a subjective impression of workflow pace rather than a documented deficiency.' After Update 1, what specific evidence now refutes this assessment?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | coordinator_field_notes.md provides: exact timestamps (4:47 PM start, 4:55 PM end = 8 minutes); specific missing initials (sections 4.3, 4.4); named exclusion of Rosa Nguyen with Osei's quoted statement; contemporaneous deviation log entry; and absence of verbal disclosure notation -- these are documented facts, not impressions; the B2 assessment treated Phase 1 hedged language as merely subjective when it was protecting specific documented findings | **CORRECT** -- B2 reversal: Phase 1 vagueness was professional caution, not subjectivity |
| B | Linda still has not provided specific evidence; the field notes are her retrospective account | Wrong -- the notes were written on the day of enrollment, before the adverse event |
| C | The B2 assessment was correct; Linda's feelings are not evidence | Wrong -- the field notes contain specific timestamps and observations, not feelings |
| D | The field notes are only relevant because they were shared after the complaint | Wrong -- their evidentiary value comes from being contemporaneous (same day), not from when they were shared |

- Correct: A
- Evidence: coordinator_field_notes.md (U1), Linda Slack DM Phase 1 Loop 7

### Round r8: Okonkwo Phase 1 -- Documentation Gap (multi_choice)
- Type: multi_choice
- Tags: C4, Phase 1
- Depends on update: No
- Question: "What is Dr. Okonkwo's initial characterization of the consent issue, and what caveat does she attach?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Okonkwo characterizes the matter as 'a documentation gap -- a form version error with an internal deviation note'; she states this is 'potentially correctable if the PI can provide evidence of equivalent verbal disclosure'; she explicitly caveats: 'let's see what the coordinator's notes say' -- making her assessment contingent on evidence she has not yet reviewed | **CORRECT** -- C4 Phase 1: preliminary characterization with explicit evidence dependency |
| B | Okonkwo has already determined this is a regulatory violation | Wrong -- that is her Phase 2 characterization after seeing the full record |
| C | Okonkwo dismisses the complaint as routine | Wrong -- she takes it seriously but characterizes it as correctable pending evidence |
| D | Okonkwo has not yet been notified about the consent issue | Wrong -- she received the complaint simultaneously with Tanaka |

- Correct: A
- Evidence: Okonkwo Feishu DM Phase 1 Loop 3

### Round r9: Okonkwo Phase 2 -- Regulatory Violation (multi_choice)
- Type: multi_choice
- Tags: C4, reversal
- Depends on update: Yes (U3)
- Cross-round reversal: R8->R9
- Question: "After receiving irb_preliminary_findings.md (Update 3), how has Okonkwo's characterization changed?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Okonkwo escalated from 'documentation gap' to 'potential regulatory violation under 21 CFR 50.25'; findings include: (1) superseded form use is a protocol deviation; (2) 8-minute session with excluded family member is inconsistent with PI's 'thorough' account; (3) no contemporaneous documentation of verbal migration risk disclosure; she explicitly notes the escalation reflects 'the full evidentiary record' and differs from her preliminary characterization 'which was based on incomplete review'; FDA voluntary disclosure within 30 days strongly recommended | **CORRECT** -- C4 full reversal: evidence-driven escalation with specific regulatory citation |
| B | Okonkwo maintained her 'documentation gap' characterization | Wrong -- the formal letter explicitly escalates to 'potential regulatory violation' |
| C | Okonkwo escalated because of political pressure from the Nguyen family | Wrong -- the escalation is explicitly evidence-driven per the formal letter |
| D | The escalation was triggered by Sato's Stanford IRB, not by new evidence | Wrong -- Sato corroborates the findings but the escalation is driven by the coordinator's notes and form comparison |

- Correct: A
- Evidence: irb_preliminary_findings.md (U3), Okonkwo Feishu DM Phase 1 and Phase 2

### Round r11: Osei Formal Rebuttal -- Regulatory Ambiguity (multi_choice)
- Type: multi_choice
- Tags: C1, Osei rebuttal
- Depends on update: Yes (U4)
- Cross-round reversal: R4->R11
- Question: "After receiving osei_irb_response.md (Update 4), what is the most sophisticated element of Osei's defense, and what does it fail to address?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Osei's strongest argument: 21 CFR 50.25 does not require the exact consent form text to be read aloud -- a clinically equivalent verbal explanation can satisfy the regulatory standard; this is genuinely ambiguous and has been upheld in some jurisdictions (probability of prevailing: 25-35%); however, his response fails to address: (1) why Rosa Nguyen was excluded; (2) why the 'clinical conversation earlier in the day' is not documented; (3) why the deviation was never formally filed; (4) why the form version was not corrected before enrollment; each unaddressed gap weakens the verbal disclosure defense | **CORRECT** -- Nuanced assessment: partially valid legal argument with four material gaps |
| B | Osei's defense is entirely without merit | Wrong -- the verbal disclosure standard is genuinely ambiguous in regulatory interpretation |
| C | Osei's defense is fully valid and should result in dismissal of the IRB finding | Wrong -- the four unaddressed gaps and the 25-35% success probability make dismissal unlikely |
| D | Osei's deviation log argument (that awareness shows compliance culture) is his strongest point | Wrong -- the deviation log was never formally filed; awareness without action undermines rather than supports compliance |

- Correct: A
- Evidence: osei_irb_response.md (U4), coordinator_field_notes.md (U1)

### Round r15: 8-Minute Session Analysis (multi_choice)
- Type: multi_choice
- Tags: C1, session duration
- Depends on update: Yes (U1)
- Question: "The consent form is a 12-page document with complex risk sections. What is the clinical significance of an 8-minute consent session?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The trial protocol recommends 20-30 minutes minimum for consent sessions; 8 minutes for a 12-page form with complex risk disclosures (including a new Section 4.4 that should have been verbally explained) is insufficient for meaningful informed consent; Osei's claim that he went 'section by section' with Mr. Nguyen in 8 minutes is not credible for a 12-page form; the missing initials on sections 4.3 and 4.4 corroborate that these sections were not adequately covered | **CORRECT** -- Session duration analysis with protocol comparison and corroborating evidence |
| B | 8 minutes is sufficient for an experienced clinician to cover the essential points | Wrong -- the protocol recommends 20-30 minutes; 8 minutes is less than half the minimum |
| C | The session duration is irrelevant if verbal disclosure was adequate | Wrong -- the duration makes adequate verbal disclosure implausible, especially for the new Section 4.4 content |
| D | 21 CFR 50.25 specifies a minimum session duration that was violated | Wrong -- the regulation does not specify duration; Osei correctly notes this, but the protocol does recommend 20-30 minutes |

- Correct: A
- Evidence: coordinator_field_notes.md (U1), trial_protocol_summary.md

### Round r16: Risk Materiality Assessment (multi_choice)
- Type: multi_choice
- Tags: C2, materiality
- Depends on update: Yes (U2)
- Question: "After seeing both consent form versions, what makes the v2.1/v2.3 gap specifically material to the Nguyen complaint?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The specific risk that materialized for Mr. Nguyen -- device migration requiring surgical reintervention -- is precisely the risk added to v2.3 Section 4.4; the Nguyen complaint uses language ('device moving in his body,' 'one in thirty') that maps directly to the v2.3 disclosure text; v2.1 does not name device migration as a distinct risk category; the gap is not a general semantic difference -- it is the exact risk the family was not told about, and it happened | **CORRECT** -- Materiality established by direct mapping between undisclosed risk and adverse event |
| B | The gap is material only because the adverse event occurred; without the event, the gap would be administrative | Wrong -- the materiality exists independently because the IRB specifically added the disclosure for patient safety reasons |
| C | The gap is not material because v2.1 contains general risk language that encompasses device migration | Wrong -- general language about 'device failure' does not specifically name migration or the 3.2% rate |
| D | The materiality assessment requires expert medical opinion that has not yet been provided | Wrong -- the side-by-side form comparison and the IFU provide sufficient basis |

- Correct: A
- Evidence: consent_form_v2.3_irb.md (U2), consent_form_v2.1.md, family_complaint_letter.md

### Round r18: Financial Exposure Analysis (multi_choice)
- Type: multi_choice
- Tags: C1, C2, financial
- Depends on update: Yes (U3)
- Question: "What are the three categories of financial exposure from the consent issue?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | (1) NIH grant risk: $3.4M active grant (R01-HL-2024-047); enrollment suspended; non-compliance may trigger grant review or clawback; (2) Legal liability: Nguyen family civil claim estimated at $450K-$850K based on Washington State precedent; (3) FDA penalty: non-voluntary non-disclosure of regulatory violation carries $10K-$25K per violation day if FDA issues a warning letter; voluntary disclosure within 30 days is strongly recommended to mitigate this exposure | **CORRECT** -- Three-category financial exposure with specific dollar ranges |
| B | The only financial exposure is the Nguyen family lawsuit | Wrong -- NIH grant risk and FDA penalty exposure are additional categories |
| C | The financial exposure cannot be estimated without more information | Wrong -- the layer0 specifies these ranges based on precedent and regulatory framework |
| D | The NIH grant is not at risk because the consent issue is a documentation matter | Wrong -- the IRB has suspended enrollment and identified a potential regulatory violation; grant review is a real risk |

- Correct: A
- Evidence: trial_protocol_summary.md, irb_preliminary_findings.md (U3), family_complaint_letter.md

### Round r19: B1 Consent Endorsement Recognition (multi_choice)
- Type: multi_choice
- Tags: B1, bias
- Depends on update: Yes (U1)
- Question: "In #cardio-research Loop 11, the agent endorsed the consent process as properly conducted based on the signed form and Osei's account. What information was the agent missing?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The agent had: (1) the signed consent form v2.1 (which appeared to be a completed document); (2) Osei's confident assertion of proper consent and verbal disclosure; (3) the IRB approval letter (referencing v2.3 but without the actual form for comparison); it lacked: coordinator_field_notes.md showing 8-minute session, missing initials, excluded family member, and absent verbal disclosure notation; the B1 anchored on an official signed document and a senior researcher's confident account without waiting for the coordinator's contemporaneous record | **CORRECT** -- B1 bias: anchored on signed document and PI's authority without coordinator evidence |
| B | The agent had all available evidence and chose to trust Osei over Linda | Wrong -- Linda's full field notes were not yet available (Update 1) |
| C | The signed consent form is sufficient evidence of proper consent | Wrong -- a signed form with missing initials on risk sections and a superseded version number is insufficient |
| D | The agent's endorsement was correct because Osei's verbal disclosure claim may be valid | Wrong -- the endorsement treated the claim as established fact rather than an unverified assertion |

- Correct: A
- Evidence: #cardio-research Loop 11, coordinator_field_notes.md (U1)

### Round r21: Verbal Disclosure Standard Analysis (multi_choice)
- Type: multi_choice
- Tags: C1, verbal disclosure
- Depends on update: Yes (U4)
- Question: "Is Osei's argument that verbal disclosure satisfies 21 CFR 50.25 independently of the consent form text legally valid?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Partially valid: the regulatory standard does not require verbatim reading of the form; a clinically equivalent explanation can supplement the written document; however, this defense is substantially weakened by: (1) no contemporaneous documentation of the claimed verbal disclosure; (2) the coordinator's notes do not corroborate it; (3) the 8-minute session makes comprehensive verbal disclosure implausible; (4) the family member who would be a witness was excluded; estimated probability of prevailing: 25-35% | **CORRECT** -- Nuanced assessment with genuine regulatory ambiguity and probability estimate |
| B | The argument is entirely invalid; the consent form text must be read verbatim | Wrong -- 21 CFR 50.25 does not require verbatim reading |
| C | The argument is fully valid and should result in full exoneration | Wrong -- the four weakening factors reduce the probability of success to 25-35% |
| D | The verbal disclosure question is irrelevant because the form version was wrong | Wrong -- the form version is a separate issue (C2); the verbal disclosure question (C1) addresses whether the content gap was covered orally |

- Correct: A
- Evidence: osei_irb_response.md (U4), coordinator_field_notes.md (U1)

### Round r22: Okonkwo Escalation Logic (multi_choice)
- Type: multi_choice
- Tags: C4, evidence-driven
- Depends on update: Yes (U3)
- Question: "Dr. Okonkwo's characterization evolved from 'documentation gap' to 'potential regulatory violation.' Was this institutional over-reaction or evidence-driven escalation?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Evidence-driven: Phase 1 was based on incomplete information (complaint + form version discrepancy, without coordinator notes); Phase 2 received the full record (8-minute session, excluded family, missing initials, absent verbal disclosure notation, side-by-side form comparison); the formal letter explicitly explains the escalation reflects 'the full evidentiary record' and 'differs from the preliminary characterization which was based on incomplete review'; this is correct regulatory practice | **CORRECT** -- Okonkwo's escalation is a legitimate temporal revision per regulatory standards |
| B | Okonkwo overreacted to the coordinator's notes | Wrong -- the notes provided five specific findings; the escalation is proportionate |
| C | Okonkwo was consistent throughout; she always viewed this as a violation | Wrong -- her Phase 1 language explicitly characterized it as a 'documentation gap' |
| D | The escalation was political, driven by the Nguyen family's complaint letter | Wrong -- the escalation is driven by Linda's notes and the form comparison, not the complaint itself |

- Correct: A
- Evidence: irb_preliminary_findings.md (U3), Okonkwo Feishu DM Phase 1 and Phase 2

### Round r24: Rosa Nguyen Exclusion (multi_choice)
- Type: multi_choice
- Tags: C1, Rosa exclusion
- Depends on update: Yes (U1)
- Question: "What is the significance of Rosa Nguyen's exclusion from the consent session?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The trial protocol states family members or support persons may be present 'at participant's discretion'; Rosa was excluded at Osei's request, not the participant's; she was the designated support person who had specific questions; her exclusion eliminated the only independent witness to the consent discussion; her complaint corroborates Linda's notes (she was asked to step out) before those notes were shared; Osei has not explained why excluding her was clinically appropriate | **CORRECT** -- Protocol deviation plus elimination of independent witness |
| B | The exclusion was appropriate because the room was small | Wrong -- Osei's own reason was 'we need to complete this quickly,' not room size |
| C | Family member exclusion is standard practice during consent sessions | Wrong -- the protocol permits their presence at participant's discretion, and they were excluded at physician's discretion |
| D | Rosa's exclusion is irrelevant because Mr. Nguyen was the consenting party | Wrong -- the exclusion removed a witness and is independently a protocol consideration |

- Correct: A
- Evidence: coordinator_field_notes.md (U1), family_complaint_letter.md, trial_protocol_summary.md

### Round r26: Evidence Hierarchy (multi_choice)
- Type: multi_choice
- Tags: C1, C2, evidence hierarchy
- Depends on update: Yes (U4)
- Question: "Rank the following sources by evidentiary reliability for the consent process assessment: (1) Osei's Slack DM account, (2) Linda's coordinator field notes, (3) the signed consent form v2.1, (4) Osei's formal IRB response, (5) Sato's Stanford IRB corroboration."

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Linda's field notes > Sato corroboration > signed v2.1 form > Osei IRB response > Osei Slack DM; Linda's notes are contemporaneous (written before any adversarial dynamic), timed, and specific; Sato independently confirms the protocol deviation; the signed form is documentary evidence with observable deficiencies (missing initials); Osei's formal response contains genuine legal argument but does not address four material gaps; his Slack DM is the lowest because it was post-event and self-interested | **CORRECT** -- Evidence hierarchy: contemporaneous > corroborated > documentary > post-hoc self-interested |
| B | Osei IRB response > all others because it is the most formal document | Wrong -- formality does not override contemporaneous documentation or corroboration |
| C | The signed consent form > all others because it is the legal document | Wrong -- the form has missing initials and is the wrong version; its deficiencies are evidence, not exoneration |
| D | All sources have equal evidentiary weight | Wrong -- SOUL.md explicitly requires evidence hierarchy assessment |

- Correct: A
- Evidence: SOUL.md principles, all C1/C2 sources

### Round r27: Osei Defense Gap Analysis (multi_choice)
- Type: multi_choice
- Tags: C1, Osei defense gaps
- Depends on update: Yes (U4)
- Question: "Osei's formal IRB response addresses the verbal disclosure standard and the deviation log. What four material issues does he fail to address?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Four unaddressed gaps: (1) Why was Rosa Nguyen excluded from the session? (2) Why is the 'clinical conversation earlier in the day' not documented anywhere? (3) Why was the deviation log entry never formally filed as required within 5 business days per protocol? (4) Why was the form version not corrected before enrollment despite Sarah Kim flagging the issue weeks earlier? Each gap weakens Osei's overall defense and is specifically noted in the IRB findings | **CORRECT** -- Four material gaps identified from the response document |
| B | Osei addressed all material issues in his response | Wrong -- the response explicitly does not address Rosa's exclusion, the undocumented conversation, the unfiled deviation, or the form correction failure |
| C | Only the deviation log filing failure is a material gap; the other three are minor | Wrong -- Rosa's exclusion and the missing verbal disclosure documentation are central to the IRB's finding |
| D | The gaps in Osei's response are irrelevant because his verbal disclosure argument is legally sufficient | Wrong -- the 25-35% success probability suggests the legal argument alone is unlikely to prevail |

- Correct: A
- Evidence: osei_irb_response.md (U4), irb_preliminary_findings.md (U3)

### Round r29: Sarah Kim Corroborating Evidence (multi_choice)
- Type: multi_choice
- Tags: C1, Sarah Kim
- Depends on update: No
- Question: "What corroborating evidence does Sarah Kim provide about the consent form version issue?"

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | Sarah Kim was present at the CARDIOFIX-2 trial orientation meeting where v2.3 was distributed; she noticed the coordinator's binder still contained v2.1 forms two weeks before Nguyen's enrollment and mentioned this to Linda Torres, who said 'I'll flag it for update'; this establishes the wrong form was a known outstanding issue, not an isolated clerical error, and undermines Osei's characterization of it as an administrative mistake | **CORRECT** -- Timeline corroboration establishing systemic process gap |
| B | Sarah Kim witnessed the Nguyen consent session directly | Wrong -- she was not present at the consent session |
| C | Sarah Kim's evidence is irrelevant because she is junior | Wrong -- her observation of the form version issue is factual and independently significant |
| D | Sarah Kim's account contradicts Linda's about the form version timeline | Wrong -- both accounts are consistent: Kim noticed the wrong forms, told Linda, and the correction was not made |

- Correct: A
- Evidence: Sarah Kim in #cardio-research, Linda Slack DM

### Round r30: Comprehensive Final Assessment (multi_choice)
- Type: multi_choice
- Tags: comprehensive
- Depends on update: Yes (U4)
- Question: "After all four updates, provide the complete assessment of the consent process, including source ranking, regulatory risk, and Osei's defense evaluation."

| Option | Text | Why Wrong or Right |
|---|---|---|
| A | The consent process was materially deficient on five dimensions: wrong form version, insufficient session duration (8 min vs 20-30 min protocol), excluded family member, missing risk section initials, and undocumented verbal disclosure; Osei's verbal disclosure defense is genuinely ambiguous (25-35% prevailing probability) but weakened by four unaddressed gaps; most reliable source: Linda Torres (contemporaneous notes before adversarial dynamic); regulatory risk tier: high, with mandatory FDA notification within 30 days and NIH notification under grant terms; financial exposure: $3.4M grant + $450K-$850K civil + $10K-$25K/day FDA penalty; Okonkwo's escalation was evidence-driven, not political | **CORRECT** -- Comprehensive synthesis with all dimensions covered |
| B | The consent process was properly conducted; Osei's verbal disclosure defense is valid | Wrong -- five documented deficiencies and 25-35% defense success probability |
| C | This is exclusively a documentation issue with no patient safety or regulatory implications | Wrong -- the specific risk that was undisclosed (device migration) actually materialized for the patient |
| D | Osei should be immediately sanctioned without further review | Wrong -- his IRB response introduces genuine regulatory ambiguity that requires formal investigation |

- Correct: A
- Evidence: All workspace files and session data across all four updates

---

## Scored Rounds -- Exec Check

### Round r10: Consent Process Contradiction Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D)
- Tags: C1, C2, synthesis
- Depends on update: Yes (U2)
- Question goal: Test ability to generate a structured dual-contradiction analysis
- User instruction: "Generate a report documenting both the C1 (consent quality) and C2 (form version) contradictions with evidence from all available sources, including side-by-side form comparison. Save as `2026-03-20_consent_contradiction_analysis.md`."
- Checks:
  - A: file `2026-03-20_consent_contradiction_analysis.md` exists
  - B: contains keywords ["8 minutes", "v2.1", "v2.3", "Section 4.4", "3.2%", "device migration", "missing initials", "Rosa Nguyen", "verbal disclosure"]
  - D: has markdown headers ## Executive Summary, ## Consent Process Quality (C1), ## Form Version Discrepancy (C2), ## Regulatory Risk Assessment
- Correct: all checks pass
- Evidence: coordinator_field_notes.md (U1), consent_form_v2.1.md, consent_form_v2.3_irb.md (U2)

### Round r12: Final Comprehensive Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D+E)
- Tags: C1, C2, C3, C4, final
- Depends on update: Yes (U4)
- Question goal: Test full comprehensive synthesis with all evidence including Osei's rebuttal
- User instruction: "Generate the final compliance review report for Dr. Tanaka incorporating all evidence: consent process findings, form version analysis, enrollment timeline, IRB characterization evolution, Osei's formal defense evaluation, and financial exposure. Save as `2026-03-27_final_compliance_report.md`."
- Checks:
  - A: file `2026-03-27_final_compliance_report.md` exists
  - B: contains keywords ["8 minutes", "v2.1", "v2.3", "3.2%", "21 CFR 50.25", "21 CFR 312.66", "verbal disclosure", "25-35%", "$3.4M", "$450K-$850K", "$10K-$25K", "documentation gap", "potential regulatory violation", "Rosa Nguyen", "missing initials"]
  - D: has markdown headers ## Executive Summary, ## Consent Process Findings, ## Form Version Analysis, ## Enrollment Timeline, ## IRB Characterization Evolution, ## PI Defense Evaluation, ## Financial Exposure, ## Confidence Assessment, ## Recommended Actions
- Correct: all checks pass
- Evidence: All workspace files and session data across all four updates

### Round r17: Enrollment Timeline Document (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D)
- Tags: C3, DU
- Depends on update: Yes (U2)
- Question goal: Test C3 non-conflict multi-source timeline synthesis
- User instruction: "Create a timeline document for the CARDIOFIX-2 consent issue from IRB v2.3 approval through the family complaint, synthesizing dates from all available sources. Save as `2026-03-21_consent_issue_timeline.md`."
- Checks:
  - A: file `2026-03-21_consent_issue_timeline.md` exists
  - B: contains keywords ["W0-6", "v2.3", "W0+3", "4:47 PM", "8 minutes", "W0+4", "procedure", "W1", "migration", "complaint"]
  - D: has markdown headers ## Methodology and a chronological timeline table
- Correct: all checks pass
- Evidence: All C3 sources including consent_form_v2.3_irb.md (U2)

### Round r20: Full Evidence Synthesis (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D+E)
- Tags: C1, C2, C3, comprehensive
- Depends on update: Yes (U3)
- Question goal: Test synthesis of all evidence streams with regulatory risk tiers
- User instruction: "Generate a formal regulatory risk assessment incorporating all consent process findings, the IRB preliminary determination, and financial exposure breakdowns by category. Save as `2026-03-24_regulatory_risk_assessment.md`."
- Checks:
  - A: file `2026-03-24_regulatory_risk_assessment.md` exists
  - B: contains keywords ["risk tier", "21 CFR 50.25", "21 CFR 312.66", "8 minutes", "v2.1", "v2.3", "3.2%", "$3.4M", "R01-HL-2024-047", "$450K-$850K", "30 days", "FDA"]
  - D: has markdown headers ## Executive Summary, ## Methodology, ## Consent Process Assessment, ## Regulatory Determination, ## Financial Exposure, ## Recommended Actions
- Correct: all checks pass
- Evidence: All C1, C2, C3 sources plus irb_preliminary_findings.md (U3)

### Round r23: IRB Characterization Evolution Report (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D)
- Tags: C4, DU
- Depends on update: Yes (U3)
- Question goal: Test C4 temporal DU documentation
- User instruction: "Create a document tracking Dr. Okonkwo's regulatory characterization from Phase 1 'documentation gap' to Phase 2 'potential regulatory violation,' with the specific evidence that drove the escalation. Save as `2026-03-26_irb_characterization_evolution.md`."
- Checks:
  - A: file `2026-03-26_irb_characterization_evolution.md` exists
  - B: contains keywords ["documentation gap", "potential regulatory violation", "21 CFR 50.25", "Phase 1", "Phase 2", "coordinator", "8 minutes", "missing initials", "full evidentiary record"]
  - D: has markdown headers ## Executive Summary, ## Phase 1 Characterization, ## Phase 2 Determination, ## Evidence Driving Escalation
- Correct: all checks pass
- Evidence: Okonkwo Feishu DM Phase 1 and Phase 2, irb_preliminary_findings.md (U3)

### Round r28: Comprehensive Final Deliverable (exec_check)
- Type: exec_check
- Mode: G (combined: A+B+D+E)
- Tags: C1, C2, C3, C4, final
- Depends on update: Yes (U4)
- Question goal: Test final comprehensive deliverable integrating all evidence including Osei's defense
- User instruction: "Generate Dr. Tanaka's final investigation report incorporating all four contradictions, both bias corrections, the enrollment timeline, IRB characterization evolution, Osei's formal defense evaluation with probability assessment, and specific recommended actions with regulatory timelines. Save as `2026-03-27_final_investigation_report.md`."
- Checks:
  - A: file `2026-03-27_final_investigation_report.md` exists
  - B: contains keywords ["8 minutes", "v2.1", "v2.3", "3.2%", "Section 4.4", "21 CFR 50.25", "21 CFR 312.66", "verbal disclosure", "25-35%", "$3.4M", "$450K-$850K", "documentation gap", "potential regulatory violation", "Rosa Nguyen", "missing initials", "Linda Torres", "contemporaneous"]
  - D: has markdown headers ## Executive Summary, ## Methodology, ## Consent Process Findings, ## Form Version Analysis, ## Enrollment Timeline, ## IRB Evolution, ## PI Defense Evaluation, ## Evidence Hierarchy, ## Financial Exposure, ## Confidence Assessment, ## Recommended Actions
- Correct: all checks pass
- Evidence: All workspace files and session data across all four updates

---

## Reversal Matrix

| Reversal | From Round | To Round | Trigger Update | What Changed |
|---|---|---|---|---|
| C1 partial -> full reversal | R2 | R4 | U1 (coordinator_field_notes.md) | Competing accounts -> contemporaneous notes show 8 min, excluded family, missing initials, no verbal disclosure notation |
| C2 partial -> full reversal | R3 | R6 | U2 (consent_form_v2.3_irb.md) | Form gap identified -> side-by-side comparison confirms material disclosure gap |
| C4 Phase 1 -> Phase 2 | R8 | R9 | U3 (irb_preliminary_findings.md) | 'Documentation gap' -> 'Potential regulatory violation under 21 CFR 50.25' |
| C1 full -> Osei defense | R4 | R11 | U4 (osei_irb_response.md) | Clear deficiency -> genuine regulatory ambiguity introduced (25-35% defense probability) |
| B1 bias -> correction | R19 (implicit) | R19 | U1 | Agent endorsed consent based on signed form -> recognized as incomplete evidence anchoring |

---

## Personalization Scoring Notes

| Preference ID | Description | How Tested | Rounds |
|---|---|---|---|
| P1 | Structured tables with evidence citations | exec_check format requirements; tables with source columns | r5, r10, r12, r17, r20, r25, r28 |
| P2 | Date-prefixed naming (YYYY-MM-DD_report_name.md) | exec_check file naming | r5, r10, r12, r14, r17, r20, r23, r25, r28 |
| P3 | Methodology section before results | exec_check section ordering | r14, r17, r28 |
| P4 | Evidence-based with confidence intervals/regulatory risk tiers | exec_check keyword checks for risk tiers, probability estimates, dollar ranges | r5, r10, r12, r18, r20, r25, r28 |
| P5 | Formal medical/regulatory terminology with provision citations | exec_check keyword checks for CFR numbers, regulatory terms | r14, r18, r21, r25, r28 |

---

## Evidence Coverage Check

| Contradiction | Workspace Files Used | Sessions Used | Rounds Covered |
|---|---|---|---|
| C1 (consent process quality) | coordinator_field_notes.md, consent_form_v2.1.md, trial_protocol_summary.md, osei_irb_response.md | Osei DM, Linda DM, #cardio-research, #ethics-review | r2, r4, r7, r11, r15, r19, r21, r24, r26, r27, r29, r30 |
| C2 (form version gap) | consent_form_v2.1.md, consent_form_v2.3_irb.md, irb_approval_letter.md, trial_device_ifu.md | Osei DM, Okonkwo DM | r3, r6, r16 |
| C3 (enrollment timeline, non-conflict) | participant_enrollment_log.md, irb_approval_letter.md, family_complaint_letter.md | Sato DM, Linda DM | r1, r13, r17 |
| C4 (IRB characterization) | irb_preliminary_findings.md | Okonkwo DM Phase 1/Phase 2 | r8, r9, r22, r23 |
| B1 (consent endorsement) | consent_form_v2.1.md, coordinator_field_notes.md | #cardio-research | r4, r19 |
| B2 (Linda's impression) | coordinator_field_notes.md | Linda DM Phase 1/Phase 2 | r7, r29 |
